Eva Hoster

11.7k total citations · 1 hit paper
136 papers, 4.6k citations indexed

About

Eva Hoster is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Eva Hoster has authored 136 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Pathology and Forensic Medicine, 55 papers in Oncology and 46 papers in Genetics. Recurrent topics in Eva Hoster's work include Lymphoma Diagnosis and Treatment (97 papers), Chronic Lymphocytic Leukemia Research (44 papers) and Viral-associated cancers and disorders (38 papers). Eva Hoster is often cited by papers focused on Lymphoma Diagnosis and Treatment (97 papers), Chronic Lymphocytic Leukemia Research (44 papers) and Viral-associated cancers and disorders (38 papers). Eva Hoster collaborates with scholars based in Germany, France and Netherlands. Eva Hoster's co-authors include Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling, Bernhard Wörmann, Wolfram Klapper, Bernd Metzner, Joerg Hasford, Hannes Wandt, Michael Pfreundschuh and Hartmut Eimermacher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Eva Hoster

130 papers receiving 4.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Eva Hoster, Martin Dreyling et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Eva Hoster	3.1k	2.3k	1.6k	691	681	136	4.6k
Carsten Utoft Niemann	1.8k 0.6×	839 0.4×	2.2k 1.4×	602 0.9×	320 0.5×	154	3.6k
Jan Paul de Boer	1.1k 0.4×	1.6k 0.7×	324 0.2×	363 0.5×	788 1.2×	118	3.9k
M. D’Incan	1.6k 0.5×	754 0.3×	708 0.4×	461 0.7×	259 0.4×	144	4.1k
Maya H Buch	1.1k 0.4×	575 0.2×	996 0.6×	560 0.8×	658 1.0×	211	6.4k
Thasia Woodworth	760 0.2×	870 0.4×	642 0.4×	768 1.1×	289 0.4×	84	7.4k
Alain Cantagrel	769 0.2×	625 0.3×	861 0.5×	605 0.9×	345 0.5×	202	7.5k
Helen S. L. Chan	464 0.2×	1.6k 0.7×	768 0.5×	1.3k 1.9×	944 1.4×	107	4.6k
Gordon L. Phillips	624 0.2×	1.0k 0.4×	514 0.3×	476 0.7×	490 0.7×	87	3.8k
Patrick Durez	969 0.3×	690 0.3×	1.3k 0.8×	535 0.8×	198 0.3×	205	7.2k
Hans‐Peter Tony	649 0.2×	866 0.4×	660 0.4×	438 0.6×	222 0.3×	151	4.4k

Countries citing papers authored by Eva Hoster

Since Specialization

Citations

This map shows the geographic impact of Eva Hoster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hoster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hoster more than expected).

Fields of papers citing papers by Eva Hoster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hoster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hoster. The network helps show where Eva Hoster may publish in the future.

Co-authorship network of co-authors of Eva Hoster

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Hoster. A scholar is included among the top collaborators of Eva Hoster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Hoster. Eva Hoster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Christian, Marek Trněný, Eva Giné, et al.. (2024). Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B). Blood. 144(Supplement 1). 4422.3–4422.3. 2 indexed citations

Jiang, Linmiao, Karol Pál, Peter J. Stewart, et al.. (2024). Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials. Leukemia. 38(12). 2675–2684. 4 indexed citations

Jiang, Linmiao, Martin Dreyling, Olivier Hermine, et al.. (2024). Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network. British Journal of Haematology. 206(1). 159–166. 1 indexed citations

Ohler, Anke, Christian Schmidt, Michael Unterhalt, et al.. (2024). Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III. Blood. 144(Supplement 1). 3042.2–3042.2.

Metzner, Bernd, Thomas Müller, Jochen Casper, et al.. (2023). Long‐term outcome in patients with mantle cell lymphoma following high‐dose therapy and autologous stem cell transplantation. European Journal Of Haematology. 111(2). 220–228. 1 indexed citations

Knösel, Thomas, Sandra E. Hasmann, Clemens Scherer, et al.. (2022). Thyroidal Angiotensin-Converting Enzyme 2 Protein Expression and Thyroid Function Tests in Patients with COVID-19: Results from a Retrospective Case Series and a Prospective Cohort Study. Thyroid. 33(2). 177–185. 5 indexed citations

Casulo, Carla, Jesse G. Dixon, Fang‐Shu Ou, et al.. (2021). Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances. 5(6). 1737–1745. 3 indexed citations

Thurner, Lorenz, Natalie Fadle, Joerg Thomas Bittenbring, et al.. (2021). LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. Blood. 137(23). 3251–3258. 7 indexed citations

Frank‐Raue, Karin, Friedhelm Raue, Eva Hoster, et al.. (2020). Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Thyroid. 31(3). 459–469. 46 indexed citations

10.

Alig, Stefan, Vindi Jurinović, Alessandro Pastore, et al.. (2019). Impact of age on clinical risk scores in follicular lymphoma. Blood Advances. 3(7). 1033–1038. 15 indexed citations

11.

Pott, Christiane, Eva Hoster, Michael Unterhalt, et al.. (2018). Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. Blood. 132(Supplement 1). 396–396. 20 indexed citations

12.

Aukema, Sietse, Eva Hoster, Andreas Rosenwald, et al.. (2017). Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 131(4). 417–420. 81 indexed citations

13.

Pott, Christiane, Henrik Knecht, Elisa Genuardi, et al.. (2017). Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma. Blood. 130. 1491–1491. 7 indexed citations

14.

Koch, Karoline, Eva Hoster, Marita Ziepert, et al.. (2016). Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Annals of Oncology. 27(7). 1323–1329. 42 indexed citations

15.

Kluin‐Nelemans, Hanneke C., Eva Hoster, Olivier Hermine, et al.. (2011). R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN: FIRST RESULTS OF A RANDOMIZED TRIAL FOR ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA. Annals of Oncology. 22. 86–86. 4 indexed citations

16.

Dufour, Annika, Friederike Schneider, Klaus H. Metzeler, et al.. (2009). Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome. Journal of Clinical Oncology. 28(4). 570–577. 189 indexed citations

17.

Schneider, Friederike, Eva Hoster, Michael Unterhalt, et al.. (2009). NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 113(21). 5250–5253. 48 indexed citations

18.

Hartmann, Elena, Verónica Fernández, Vı́ctor Moreno, et al.. (2008). Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Clinical Oncology. 26(30). 4966–4972. 85 indexed citations

19.

Nickenig, Christina, Eva Hoster, Wolfgang Ludwig, et al.. (2006). Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Annals of Oncology. 18(1). 136–142. 13 indexed citations

20.

Nickenig, Christina, Martin Dreyling, Eva Hoster, et al.. (2005). MCP (Mitoxantrone/Chlorambucil/Prednisolone) Chemotherapy Impairs the Subsequent Collection of Stem Cells in Comparison to CHOP Induction in Patients with Indolent Lymphomas - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).. Blood. 106(11). 3331–3331. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact